Almirall, S.A.

MCE ALM.MC

Almirall, S.A. Total Non-Current Liabilities for the year ending December 31, 2023: USD 618.66 M

Almirall, S.A. Total Non-Current Liabilities is USD 618.66 M for the year ending December 31, 2023, a 4.30% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Almirall, S.A. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 593.14 M, a -9.34% change year over year.
Almirall, S.A. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 654.22 M, a 4.28% change year over year.
Almirall, S.A. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 627.38 M, a -33.69% change year over year.
Almirall, S.A. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 946.12 M, a -13.32% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

MCE: ALM.MC

Almirall, S.A.

CEO	Mr. Carlos Gallardo Piqué
IPO Date	June 20, 2007
Location	Spain
Headquarters	Ronda Del General Miter, 151
Employees	1,904
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Perfumes & Fragrances Personal Care

Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Key trends

Past 5 years